Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Personalis, Inc.

< Previous 1 2 3 4 Next >
New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and Tempus Expand Collaboration to Biopharma
From Personalis, Inc.
Via Business Wire
Tickers PSNL TEM
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Third Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at the Stifel 2024 Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Third Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at Upcoming Investor Conferences
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis and Tempus Announce Expanded Collaboration
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce Second Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
From Personalis, Inc.
Via Business Wire
Tickers PSNL
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis Reports First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Announce First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Tickers PSNL
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Personalis, Inc.
Via Business Wire
Tickers PSNL
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.